GB1472342A - Derivatives of 2-2-pyridylcarbonyl-indole - Google Patents
Derivatives of 2-2-pyridylcarbonyl-indoleInfo
- Publication number
- GB1472342A GB1472342A GB299475A GB299475A GB1472342A GB 1472342 A GB1472342 A GB 1472342A GB 299475 A GB299475 A GB 299475A GB 299475 A GB299475 A GB 299475A GB 1472342 A GB1472342 A GB 1472342A
- Authority
- GB
- United Kingdom
- Prior art keywords
- indole
- prepared
- derivatives
- substituted
- picolyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
Abstract
1472342 Derivatives of 2-(2-picolyl)indole CIBA-GEIGY AG 23 Jan 1975 [25 Jan 1974] 2994/75 Heading C2C The invention comprises indoles-and their salts-which are substituted (a) in the 1-position by aliphatic hydrocarbyl (possibly aryl-substituted), and (b) in the 2-position by (possibly C 1-7 -alkyl substituted) picolinoyl or alphahydroxypicolyl, and optionally (c) in other ring positions. In examples, these compounds are prepared by (1) reducing the ketones to carbinols, or the reverse oxidation process, (2) converting substituent methoxy groups to OH, or (3) reacting together either (i) a 2-lithioindole with 2-formylpyridine or 2-picolinic acid, or (ii) a 2-lithiopyridine with the corresponding indole- 2-carboxylic acid (which reagents are themselves prepared by hydrolysis of the methyl or ethyl esters). The acids may react in the form of their Li salts. Starting materials otherwise prepared have the formula 2,5-MeNH(Cl)C 6 H 3 X, where X is CONHNH 2 , CONHNHO 2 SC 6 H 4 Me(-p) or CHO. Therapeutic compositions having fibrinolytic, thrombolytic and platelet aggregation inhibitive activity, comprise the above 2-(2-picolyl)indole derivatives, and may be administered orally or parenterally.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CH104774 | 1974-01-25 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| GB1472342A true GB1472342A (en) | 1977-05-04 |
Family
ID=4201215
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| GB299475A Expired GB1472342A (en) | 1974-01-25 | 1975-01-23 | Derivatives of 2-2-pyridylcarbonyl-indole |
Country Status (14)
| Country | Link |
|---|---|
| JP (1) | JPS50106969A (en) |
| AT (1) | ATA53175A (en) |
| AU (1) | AU7756375A (en) |
| BE (1) | BE824742A (en) |
| DE (1) | DE2501468A1 (en) |
| DK (1) | DK3375A (en) |
| ES (1) | ES434079A1 (en) |
| FR (1) | FR2258853B1 (en) |
| GB (1) | GB1472342A (en) |
| IE (1) | IE40368B1 (en) |
| IL (1) | IL46505A0 (en) |
| NL (1) | NL7500535A (en) |
| SE (1) | SE7500262L (en) |
| ZA (1) | ZA75522B (en) |
Cited By (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2001082909A2 (en) * | 2000-04-28 | 2001-11-08 | Baxter Healthcare Sa | 2-acyl indol derivatives and their use as anti-tumour agents |
| DE10152306A1 (en) * | 2001-10-26 | 2003-07-24 | Asta Medica Ag | 2-acylindole derivatives with new therapeutically valuable properties |
| US8680108B2 (en) | 2009-12-18 | 2014-03-25 | Incyte Corporation | Substituted fused aryl and heteroaryl derivatives as PI3K inhibitors |
| US8759359B2 (en) | 2009-12-18 | 2014-06-24 | Incyte Corporation | Substituted heteroaryl fused derivatives as PI3K inhibitors |
| US8940752B2 (en) | 2009-06-29 | 2015-01-27 | Incyte Corporation | Pyrimidinones as PI3K inhibitors |
| US9062055B2 (en) | 2010-06-21 | 2015-06-23 | Incyte Corporation | Fused pyrrole derivatives as PI3K inhibitors |
| US9096600B2 (en) | 2010-12-20 | 2015-08-04 | Incyte Corporation | N-(1-(substituted-phenyl)ethyl)-9H-purin-6-amines as PI3K inhibitors |
| US9108984B2 (en) | 2011-03-14 | 2015-08-18 | Incyte Corporation | Substituted diamino-pyrimidine and diamino-pyridine derivatives as PI3K inhibitors |
| US9126948B2 (en) | 2011-03-25 | 2015-09-08 | Incyte Holdings Corporation | Pyrimidine-4,6-diamine derivatives as PI3K inhibitors |
| US9193721B2 (en) | 2010-04-14 | 2015-11-24 | Incyte Holdings Corporation | Fused derivatives as PI3Kδ inhibitors |
| US9199982B2 (en) | 2011-09-02 | 2015-12-01 | Incyte Holdings Corporation | Heterocyclylamines as PI3K inhibitors |
| US9309251B2 (en) | 2012-04-02 | 2016-04-12 | Incyte Holdings Corporation | Bicyclic azaheterocyclobenzylamines as PI3K inhibitors |
| US9732097B2 (en) | 2015-05-11 | 2017-08-15 | Incyte Corporation | Process for the synthesis of a phosphoinositide 3-kinase inhibitor |
| US9988401B2 (en) | 2015-05-11 | 2018-06-05 | Incyte Corporation | Crystalline forms of a PI3K inhibitor |
| US10077277B2 (en) | 2014-06-11 | 2018-09-18 | Incyte Corporation | Bicyclic heteroarylaminoalkyl phenyl derivatives as PI3K inhibitors |
| US10336759B2 (en) | 2015-02-27 | 2019-07-02 | Incyte Corporation | Salts and processes of preparing a PI3K inhibitor |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4999186A (en) * | 1986-06-27 | 1991-03-12 | The Procter & Gamble Company | Novel sunscreen agents, sunscreen compositions and methods for preventing sunburn |
| US20100298343A1 (en) * | 2007-10-05 | 2010-11-25 | John Howard Hutchinson | 5-lipoxygenase-activating protein (flap) inhibitors |
-
1975
- 1975-01-08 DK DK3375*BA patent/DK3375A/da unknown
- 1975-01-10 SE SE7500262A patent/SE7500262L/xx unknown
- 1975-01-16 NL NL7500535A patent/NL7500535A/en unknown
- 1975-01-16 DE DE19752501468 patent/DE2501468A1/en active Pending
- 1975-01-23 AU AU77563/75A patent/AU7756375A/en not_active Expired
- 1975-01-23 ES ES434079A patent/ES434079A1/en not_active Expired
- 1975-01-23 GB GB299475A patent/GB1472342A/en not_active Expired
- 1975-01-23 FR FR7502129A patent/FR2258853B1/fr not_active Expired
- 1975-01-24 IL IL46505A patent/IL46505A0/en unknown
- 1975-01-24 BE BE152675A patent/BE824742A/en unknown
- 1975-01-24 ZA ZA00750522A patent/ZA75522B/en unknown
- 1975-01-24 IE IE137/75A patent/IE40368B1/en unknown
- 1975-01-24 AT AT53175A patent/ATA53175A/en not_active IP Right Cessation
- 1975-01-25 JP JP50010179A patent/JPS50106969A/ja active Pending
Cited By (38)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2001082909A3 (en) * | 2000-04-28 | 2002-03-14 | Asta Medica Ag | 2-acyl indol derivatives and their use as anti-tumour agents |
| WO2001082909A2 (en) * | 2000-04-28 | 2001-11-08 | Baxter Healthcare Sa | 2-acyl indol derivatives and their use as anti-tumour agents |
| DE10152306A1 (en) * | 2001-10-26 | 2003-07-24 | Asta Medica Ag | 2-acylindole derivatives with new therapeutically valuable properties |
| US10829502B2 (en) | 2009-06-29 | 2020-11-10 | Incyte Corporation | Pyrimidinones as PI3K inhibitors |
| US9975907B2 (en) | 2009-06-29 | 2018-05-22 | Incyte Holdings Corporation | Pyrimidinones as PI3K inhibitors |
| US11401280B2 (en) | 2009-06-29 | 2022-08-02 | Incyte Holdings Corporation | Pyrimidinones as PI3K inhibitors |
| US8940752B2 (en) | 2009-06-29 | 2015-01-27 | Incyte Corporation | Pyrimidinones as PI3K inhibitors |
| US9434746B2 (en) | 2009-06-29 | 2016-09-06 | Incyte Corporation | Pyrimidinones as PI3K inhibitors |
| US10428087B2 (en) | 2009-06-29 | 2019-10-01 | Incyte Corporation | Pyrimidinones as PI3K inhibitors |
| US8759359B2 (en) | 2009-12-18 | 2014-06-24 | Incyte Corporation | Substituted heteroaryl fused derivatives as PI3K inhibitors |
| US9403847B2 (en) | 2009-12-18 | 2016-08-02 | Incyte Holdings Corporation | Substituted heteroaryl fused derivatives as P13K inhibitors |
| US8680108B2 (en) | 2009-12-18 | 2014-03-25 | Incyte Corporation | Substituted fused aryl and heteroaryl derivatives as PI3K inhibitors |
| US9193721B2 (en) | 2010-04-14 | 2015-11-24 | Incyte Holdings Corporation | Fused derivatives as PI3Kδ inhibitors |
| US9062055B2 (en) | 2010-06-21 | 2015-06-23 | Incyte Corporation | Fused pyrrole derivatives as PI3K inhibitors |
| US9096600B2 (en) | 2010-12-20 | 2015-08-04 | Incyte Corporation | N-(1-(substituted-phenyl)ethyl)-9H-purin-6-amines as PI3K inhibitors |
| US9527848B2 (en) | 2010-12-20 | 2016-12-27 | Incyte Holdings Corporation | N-(1-(substituted-phenyl)ethyl)-9H-purin-6-amines as PI3K inhibitors |
| US9815839B2 (en) | 2010-12-20 | 2017-11-14 | Incyte Corporation | N-(1-(substituted-phenyl)ethyl)-9H-purin-6-amines as PI3K inhibitors |
| US9108984B2 (en) | 2011-03-14 | 2015-08-18 | Incyte Corporation | Substituted diamino-pyrimidine and diamino-pyridine derivatives as PI3K inhibitors |
| US9126948B2 (en) | 2011-03-25 | 2015-09-08 | Incyte Holdings Corporation | Pyrimidine-4,6-diamine derivatives as PI3K inhibitors |
| US9707233B2 (en) | 2011-09-02 | 2017-07-18 | Incyte Holdings Corporation | Heterocyclylamines as PI3K inhibitors |
| US10376513B2 (en) | 2011-09-02 | 2019-08-13 | Incyte Holdings Corporation | Heterocyclylamines as PI3K inhibitors |
| US11819505B2 (en) | 2011-09-02 | 2023-11-21 | Incyte Corporation | Heterocyclylamines as PI3K inhibitors |
| US11433071B2 (en) | 2011-09-02 | 2022-09-06 | Incyte Corporation | Heterocyclylamines as PI3K inhibitors |
| US9199982B2 (en) | 2011-09-02 | 2015-12-01 | Incyte Holdings Corporation | Heterocyclylamines as PI3K inhibitors |
| US10092570B2 (en) | 2011-09-02 | 2018-10-09 | Incyte Holdings Corporation | Heterocyclylamines as PI3K inhibitors |
| US9730939B2 (en) | 2011-09-02 | 2017-08-15 | Incyte Holdings Corporation | Heterocyclylamines as PI3K inhibitors |
| US10646492B2 (en) | 2011-09-02 | 2020-05-12 | Incyte Corporation | Heterocyclylamines as PI3K inhibitors |
| US9309251B2 (en) | 2012-04-02 | 2016-04-12 | Incyte Holdings Corporation | Bicyclic azaheterocyclobenzylamines as PI3K inhibitors |
| US9944646B2 (en) | 2012-04-02 | 2018-04-17 | Incyte Holdings Corporation | Bicyclic azaheterocyclobenzylamines as PI3K inhibitors |
| US10259818B2 (en) | 2012-04-02 | 2019-04-16 | Incyte Corporation | Bicyclic azaheterocyclobenzylamines as PI3K inhibitors |
| US11130767B2 (en) | 2014-06-11 | 2021-09-28 | Incyte Corporation | Bicyclic heteroarylaminoalkyl phenyl derivatives as PI3K inhibitors |
| US10479803B2 (en) | 2014-06-11 | 2019-11-19 | Incyte Corporation | Bicyclic heteroarylaminoalkyl phenyl derivatives as PI3K inhibitors |
| US10077277B2 (en) | 2014-06-11 | 2018-09-18 | Incyte Corporation | Bicyclic heteroarylaminoalkyl phenyl derivatives as PI3K inhibitors |
| US10336759B2 (en) | 2015-02-27 | 2019-07-02 | Incyte Corporation | Salts and processes of preparing a PI3K inhibitor |
| US11084822B2 (en) | 2015-02-27 | 2021-08-10 | Incyte Corporation | Salts and processes of preparing a PI3K inhibitor |
| US10125150B2 (en) | 2015-05-11 | 2018-11-13 | Incyte Corporation | Crystalline forms of a PI3K inhibitor |
| US9988401B2 (en) | 2015-05-11 | 2018-06-05 | Incyte Corporation | Crystalline forms of a PI3K inhibitor |
| US9732097B2 (en) | 2015-05-11 | 2017-08-15 | Incyte Corporation | Process for the synthesis of a phosphoinositide 3-kinase inhibitor |
Also Published As
| Publication number | Publication date |
|---|---|
| JPS50106969A (en) | 1975-08-22 |
| FR2258853B1 (en) | 1978-06-30 |
| NL7500535A (en) | 1975-07-29 |
| ATA53175A (en) | 1977-08-15 |
| AU7756375A (en) | 1976-07-29 |
| IL46505A0 (en) | 1975-04-25 |
| DE2501468A1 (en) | 1975-07-31 |
| IE40368B1 (en) | 1979-05-09 |
| FR2258853A1 (en) | 1975-08-22 |
| ES434079A1 (en) | 1977-03-01 |
| DK3375A (en) | 1975-09-15 |
| IE40368L (en) | 1975-07-25 |
| ZA75522B (en) | 1976-01-28 |
| BE824742A (en) | 1975-07-24 |
| SE7500262L (en) | 1975-07-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| GB1472342A (en) | Derivatives of 2-2-pyridylcarbonyl-indole | |
| GB1324646A (en) | Nitrofurylpyrimidine derivatives | |
| GB1305793A (en) | ||
| GB1421774A (en) | Imidazolyl-2-carbinols and process for preparing them | |
| GB1359542A (en) | Diglycidyl derivatives of n-heterocyclic compounds processes for their production and the use thereof | |
| GB1314830A (en) | Pharmaceutically useful benzomorphanes and their production | |
| GB1472473A (en) | Crystalline prostanoic acid esters | |
| GB1265279A (en) | ||
| GB1252329A (en) | ||
| GB1496491A (en) | Dihydroergopeptine derivatives | |
| GB1432503A (en) | Cycloalkylalkylesters and process for their preparation | |
| GB1378068A (en) | Citric acid derivatives | |
| GB1397647A (en) | Thiophene derivatives | |
| GB1273705A (en) | A method for producing 3,5-diaryl-4-pyrazole acetic acids | |
| GB1427114A (en) | Derivatives of 3- p-chlorobenoyl-2-methyl-phenylacetic acid | |
| GB1478374A (en) | Piperidyl-methylenedioxybenzene derivatives | |
| GB1299201A (en) | Medicaments derived from thiazolidine carboxylic acid | |
| GB1250303A (en) | ||
| GB1338023A (en) | Pyridylamino-methylenemalonates | |
| GB1397434A (en) | Evomonoside derivatives | |
| GB1389461A (en) | Pyridine-acetic acid derivatives | |
| GB1395110A (en) | Derivatives of pyridine-3-acetic acid | |
| GB1212613A (en) | 4-quinazolone derivatives and process for the preparation thereof | |
| GB1243038A (en) | New cyclohexenylacetic acid derivatives and process for preparing them | |
| GB1504683A (en) | Pharmaceutical compositions containing substituted pyrimido-quinoline derivatives |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PS | Patent sealed [section 19, patents act 1949] | ||
| PCNP | Patent ceased through non-payment of renewal fee |